ARYA MITRA SHARMA
MD, PhD, FRCPC
BUSINESS ADDRESS: McMaster University, Hamilton General Hospital, 237 Barton Street East,
Hamilton, ON L8L 2X2, Canada, Tel: 905-527-4322 x46806, Fax: 905-5252260, sharma@cardio.on.ca
PERSONAL DATA:
Nationality: German, Status: Permanent Resident of Canada,
DOB: Nov 22, 1959, Wife: Christine, Daughters: Linnie (1982), Kamala
(1994), Rashmi (1986)
AREAS OF EXPERTISE:Obesity, hypertension, insulin resistance, renin-angiotensin system,
sympathetic nervous system, adipose-tissue biology, gene-expression
analysis, genetics, electrolyte and acid-base homeostasis, dietary
interventions, pharmacology
CURRENT POSITIONS
01/2006 - present
Scientific Director, Canadian Obesity Network (Network of Centres of
Excellence)
06/2003 - present
Director, Centre for Obesity Research and Management (Hamilton Health
Sciences, Hamilton, ON)
09/2002 - present
Professor of Medicine, Michael G. DeGroote School of Medicine, McMaster
University (Hamilton, ON)
PREVIOUS POSITIONS
06/2000-08/2002
Research Group Leader "Cardiovascular and Obesity Genetics", Max
Delbrück Center for Molecular Medicine, Berlin, Germany
04/2000-08/2002
Professor of Medicine, Assoc. Director, Division of Nephrology and
Hypertension, Humboldt University of Berlin, Germany
10/1995-05/2000
Professor of Medicine, Division of Nephrology and Endocrinology, Free
University of Berlin, Germany
11/1986-09/1995
Physician, Division of Internal Medicine, University Clinic Benjamin
Franklin, Free University Berlin, Germany
EDUCATION
02/1995
02/1994-02/1995
1.7-1.8-1992
5.10-16.11.1990
18.8-31.8.1990
08/1987
1979-1986
Professorial thesis (Habilitation) in Internal Medicine, Freie Universität
Berlin: “Studies on Salt Sensitivity on Normotensive Men”
Visiting Researcher: (Deutsche Forschungsgemeinschaft): J.-M. Lalouel,
Eccles Institute of Genetics, Salt Lake City, Utah, USA
Visiting Researcher: DC Batlle, Northwestern University Medical School
and Lakeside Veterans Administration Research, Chicago, Illinois, USA
Visiting Researcher: DC Batlle, Northwestern University Medical School
and Lakeside Veterans Administration Research, Chicago, Illinois, USA
Fellow at the ‘23rd International Teaching Seminar on Cardiovascular
Epidemiology and Prevention’, Council on Epidemiology and Prevention of
the International Society and Federation of Cardiology (J. Stamler, R.
Stamler, G. Rose et al.), Ziegenhals, GDR
Ph.D. - Doctoral thesis: “Effect of Angiotensin-Converting Enzyme
Inhibition on Norepinephrine Reactivity and Catecholamine Metabolism”
(magna cum laude), Faculty of Medicine, Free University of Berlin,
Germany
MD, Freie Universität Berlin, Germany
POST-GRADUATE QUALIFICATIONS AND LICENSES
09/2002Active Member (The College of Physicians and Surgeons of Ontario)
06/2002Certification Internal Medicine and Nephrology (Fellow of the Royal College of
Physicians and Surgeons of Canada)
10/1998Board Certification "Nephrology" (Ärztekammer Berlin)
09/1993Board certification "Internal Medicine" (Ärztekammer Berlin)
HONOURS AND AWARDS:
2005
Rick Gallop Award for Research Excellence, Heart & Stroke Foundation of Ontario
2002
RD Wright Lecture, High Blood Pressure Research Council of Australia
2002
Canada Research Chair: Cardiovascular Obesity Research and Management,
McMaster University, Hamilton, Ontario
1995
Young Investigator Travel Award (German Society of Hypertension)
Arya M. Sharma, MD/PhD
1994
1994-1996
1993
1993
1992
1992
1989
Page 2
Young Investigator Travel Award (DFG Sh 35/3)
Habilitationsstipendium (DFG Sh 35/2)
Dieter Klaus Förderpreis, German Society of Hypertension
Young Scholars Travel Grant (American Society of Hypertension)
"Outstanding Clinical Research Award" of the Free University Berlin
Travel Grant (International Society of Hypertension)
Young Scholars Travel Grant (American Society of Hypertension)
ACADEMIC, PROFESSIONAL & RESEARCH COMMITTEES
2006-present
Steering Committee, International Chair on Cardiometabolic Disease
2006
Clinical Co-Chair, Health Technology Utilization Guidelines Committee for
Bariatric Surgery in Ontario
2005-present
Canadian Shield Ethics Review Board
2005-present
Obesity Canada: Obesity Practice Guidelines Committee
2004-present
Canadian Institutes of Health Research Peer Review Committee – Nutrition, Food
and Health
2004
Ad hoc Committee International Association for the Study of Obesity (IASO) and
International Federation of Obesity Surgery (IFSO)
2004
Chair: International Association for the Study of Obesity (IASO): 2010 Site
Selection Committee
2000-2002
Independent Research Group Leader at the Max-Delbrück Center for Molecular
Medicine "Cardiovascualar Genetics and Obesity"
2001-present
Steering Committee and founding faculty, Specialist Certification of Obesity
Professionals in Europe (SCOPE)
1996-2000
Elected member of the Fachbereichsrat (ruling body) of the Medical Faculty of the
FU Berlin
1999-2000
Elected coordinator of the Cardiovascular Research Programme of the Freie
Universität Berlin
1995-2002
Deputy Chairman of the Patient Information Section of the German Hypertension
Society
1995-2000
Elected faculty member of the "Institutsrat" of the Dept. of Internal Medicine
Freie Universität
1988-1992
Elected deputy representative of the non-faculty medical employees of the Dept.
of Internal Medicine in the "Institutsrat" Freie Universität Berlin
1989-1991
Elected member of the Academic Senate of the Freie Universität Berlin
CLINICAL TRIALS
International
2006-present
Member, Executive Steering Committee, Aliskiren against Various Atherometabolic Trial Outcomes in obesity or Risk elevation (AVIATOR Study; Novartis)
2006-present
Chairman, Executive Steering Committee, The 5A registry: Awareness of
Abdominal Adiposity As A marker of cardiometabolic risk (Sanofi-Aventis)
2006-present
National Coordinator, INSPIRE (Sanofi-Aventis)
2005-2006
National Coordinator, International Day for Evaluation of Abdominal obesity
(IDEA Study, Sanofi-Aventis)
2006-present
Member, Data Safety Monitory Board, A 104-Week, Double-blind,
Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and
Efficacy of Lorcaserin Hydrochloride in Obese Patients (Behavioral modification and
Lorcaserin for Obesity and Overweight Management, BLOOM; ADP356-009, Arena
pharmaceuticals)
2004
Global PI: Telmisartan in patients with mild/moderate hypertension and chronic
kidney disease (ESPRIT; Boehringer Ingelheim)
2002-2004
Global PI: A prospective, randomised, open-label, blinded end-point, forcedtitration trial to compare MICARDIS PLUS / MICARDIS HCT (telmisartan
combined with hydrochlorothiazide 80 mg/12.5 mg) to DIOVAN HCT (valsartan
combined with hydrochlorothiazide 160 mg/12.5 mg), for the control of mild-tomoderate hypertension in obese patients with type-2 diabetes mellitus using
ambulatory blood pressure monitoring. (SMOOTH Study, 502.399, Boehringer
Ingelheim)
2000
Local PI: Randomized, Multicenter, Double-Blind, Trial on the Efficacy and
Tolerability of TOPIRAMATE in obese patients (PRI/TOP-INT-31, Janssen-Cilag)
2001-present
Member, Executive Steering Committee, Sibutramine Cardiovascular
OUTcomes Trial (SCOUT Trial, Abbott Laboratories)
Arya M. Sharma, MD/PhD
2000
2000
1998
1998
1998
1997
1996
1995
National
2006-present
2000
1997
1997
1997
1995
Local
2004-present
2003-2006
1999
Page 3
National PI: Efficacy and Tolerability of ORLISTAT when used with two different
weight loss diets in obese patients (Ro 18-0647, Hofmann-La Roche)
Local PI: A Phase III, Multi-Center, Two-Arm Study to assess the efficacy and
sagety of ECOPIPAM (SCH 39166) in the treatment of obesity in subjects with
type 2 Diabetes Mellitus (P00741, Schering-Plough)
Local PI: Multi-centre, prospective, randomised, double-blind, placebocontrolled parallel-group study to examine the influence of SIBUTRAMINE 15 mg
over 12 weeks on plasma fibrinogen levels in obese patients with a BMI>30
kg/m2 and <40 kg/m2 (Knoll)
Local-PI: Clinical trial to assess the efficacy and tolerability of ORLISTAT in the
long-term treatment of obese patients with hyperlipidemia: a multicentre,
double-blind, randomised, placebo-controlled, parallel group phase IIIb trial
(M37031, Hoffman-La Roche)
Local PI: Clinical trial on the efficacy of ORLISTAT on weight reduction and
maintenance of the reduced weight (M37029, Hoffman-La Roche)
Local PI: A multi-centre, randomised, double-blind comparison of FOSINOPRIL
and AMLODIPINE men and women with hypertension associated with left
ventricular hypertrophy, with or without albuminuria, FOAM-Studie, (BristolMyers Squibb)
Local PI: Multi-centre, randomised, double-blind, placebo-controlled parallelgroup study to investigate the antihypertensive efficacy and tolerability of
IRBESARTAN and LOSARTAN in patientsn with mild to moderate hypertension
(CV 131-065). (Bristol Myers Squibb/Sanofi Winthrop)
Local PI: Efficacy and tolerability of Indapamide retard 1.5 mg (S6520).
Randomised double-blind study with INDAPAMIDE 1.5 mg vs. AMLODIPINE 5 mg
and HYDROCHLOROTHIAZIDE 25 mg. (Servier/Itherapia)
National PI: Obesity Care in Canada Evaluation Registry (SOCCER; Abbott
Laboratories)
National PI: Open, placebo run-in, multicenter study to investigate the efficacy
and safety of TELMISARTAN (40 and 80 mg QD) in 3 strata of hypertensive
patients with mild, moderate or severe renal impairment (Boehringer Ingelheim
Pharma)
Local PI: Comparison of MOXONIDINE and ENALAPRIL (MOXENA-Studie) for the
treatment of patients with essential hypertension. (Lilly)
Local PI: Multi-centre study to investigate the tolerability and efficacy of TARKA
in patients with mild to moderate essential hypertension. (Knoll)
National Co-PI: Double blind, double-dummy, active drug controlled,
randomised multi-centre, parallel group study in patients with mild to moderate
essential hypertension to assess the efficacy of MIBEFRADIL and LOSARTAN on
office blood pressure and 24-hour blood pressure. (Hoffman-La Roche)
Local PI: Multi-centre, double-blind, randomised, parallel group, dose-finding
study on the Angiotensin II - Type I -Receptor Antagonist LR-B/081 (Phase II) in
comparison with Losartan. (Menarini/Berlin Chemie)
Co-PI: Biological determinants of differences in metabolic and cardiovascular
risk-factors between South Asians and European Caucasians (Mol-SHARE; HSFC)
PI: Study on telmisartan-induced reduction of myocellular lipids (TRIM; CIHR,
HSFC, Boehringer Ingelheim)
PI: Open pilot study on the efficacy and tolerability of incremental doses of
NEBIVOLOL in obese hypertensives (1999-2000 Berlin-Chemie NEB-D-1998-016)
EDUCATIONAL ACTIVITIES
Primary Supervisor
A. Doctoral Theses:
B. Masters Theses:
C. Post-Doctoral Theses:
Primary Supervisor
A. Doctoral Theses:
B. Masters Theses:
C. Post-Doctoral Theses:
in progress
1
1
0
in progress
2
1
0
completed
10
5
1
completed
0
0
0
inactive
2
0
0
inactive
0
0
0
RECENT EXAMINATION COMMITTEES
Internal (McMaster University): Kelly Smith, Master, 2006, Ramzi Fattouh, PhD, 2006, Fahad
Razak, PhD, 2005, Valerie Taylor, PhD, 2005, Natalie Grinshtein, Masters, 2004, Heather
Cameron, PhD, 2003, Melissa Perreault, PhD, 2003, Minghua Fu, PhD, 2003
External: Julie St-Pierre , PhD, 2004 (Laval University)
Arya M. Sharma, MD/PhD
Page 4
MEDICAL RESIDENCY EXAMINER
The Objective Structured Clinical Evaluation (OSCE), 2004, 2005, 2006
STUDENT ADVISOR: Jennifer Thomas (2005-present), Russel Eyestone (2005-present), Ashley
Szpurko (2006-present), Kathleen Cunniffe (2006-present)
MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS: Canadian Hypertension Society, North
American Association for the Study of Obesity (NAASO), Canadian Society of Clinical Nutrition,
Hamilton Academy of Medicine
CONFERENCE ORGANIZER
National:
- 1st Western Canada Obesity Summit, Kananaskis, AL (2007)
- McMaster Bariatric Conference, Hamilton (2005, 2006, 2007)
- 1st National Obesity Summer Boot Camp, Station Duschesney, QC (2006)
- Obesity: Challenges and Solutions, Toronto (2006)
- Obesity: Challenges and Solutions, Montreal (2006)
- Annual Meeting of the German Institute for Blood Pressure Research, Berlin (1998)
- Scientific Meeting of the German Hypertension Society, Potsdam (1991)
- Scientific Meeting of the Nephrology Society, Berlin (1992)
International:
- 1st Session of the Working Group on Obesity and Hypertension, XVI European Meeting on
Hypertension, Madrid, June 12-15, 2006
- International Symposium on Obesity and Hypertension, Berlin, Germany (1999, 2001, 2003,
2005, 2007)
- Topical Workshop on Obesity and Hypertension at the 11th Scientific Meeting of the European
Society of Hypertension, Milan (2001)
- Meeting of the International Society of Nephrology, Berlin (2003)
- Workshop on Hypertension at the Meeting of the South Asian Society of Atherosclerosis and
Thrombosis, Mumbai, India (2000)
- Workshop on Hypertension at the Meeting of the South Asian Society of Atherosclerosis and
Thrombosis, New Delhi, India (1998)
EDITORIAL BOARDS: Adipocytes, Current Hypertension Reports, Current Hypertension Reviews,
Diabetes, Obesity & Metabolism, Hypertension, Journal of Hypertension (1999-2002), Journal of
the American Society of Hypertension, Journal of Cardiometabolic Risk
GUEST EDITOR: Journal of Molecular Medicine: Molecular aspects of obesity (Jan 2001)
Herz: Obesity: a weighty problem for cardiovascular medicine (May 2001)
AD-HOC JOURNAL REFEREE: American Journal of Hypertens, American Jouranl of Physioliology,
Archives of Medical Research, ATVB, BioTechniques, Canadian Journal of Physiology and
Pharmacology, CMAJ, Circulation, Diabetes, Diabetologia, Experimental and Clinical Endocrinology,
Diabetes and Hypertension, International Journal of Obesity, JAMA, Journal of Hypertens, Journal
of Molecular Medicine, Journal of Clinical Endocrinololgy and Metabolism, Kidney International,
Lancet, Nephrololgy Dialysis and Transplantation, Nephron, Obesity Research, Thromb Res,
Nature Clinical Practice: Endocriology & Metabolism, American Journal of Cardiology
AD-HOC GRANT REFEREE: Canadian Institutes of Health Research, Canada Research Chairs,
Heart and Stroke Foundation of Canada, Heart and Stroke Foundation of Ontario, Canadian
Diabetes Association, Wellcome Trust, Medical Research Council of South Africa, Telethon (Italy),
Canadian Foundation for Innovation
TOTAL PUBLICATIONS: Refereed Papers=222, Book Chapters=5
PUBLISHED REFEREED PAPERS
1.
Sharma AM, Staels B. Peroxisome proliferator-activated receptor {gamma}
(PPAR{gamma}) and adipose tissue -- understanding obesity-related changes in regulation
of lipid and glucose metabolism. J Clin Endocrinol Metab. 2006 Dec 5; [Epub ahead of
print]
2.
Iacobellis G, Pond CM, Sharma AM. Different "weight" of cardiac and general adiposity in
predicting left ventricle morphology. Obesity. 2006;14 :1679-84.
3.
Taylor VH, Sharma AM. A patient with personal control of the adjustable gastric band and
bulimia: a psychiatric complication. Obes Surg. 2006;16 :1386-7.
4.
Iacobellis G, Sharma AM. Hypertension in lean and obese individuals: An evenly or unevenly
dangerous condition. Nutr Metab Cardiovasc Dis. 2006 Oct 14; [Epub ahead of print]
5.
Wirth A, Scholze J, Sharma AM, Matiba B, Boenner G. Reduced left ventricular mass after
treatment of obese patients with sibutramine: An echocardiographic multicentre study.
Diabetes Obes Metab. 2006;8:674-81.
Arya M. Sharma, MD/PhD
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Page 5
Shubair MM, Prabhakaran P, Pavlova V, Velianou JL, Sharma AM, Natarajan MK. The
relationship of body mass index to outcomes after percutaneous coronary intervention. J
Interv Cardiol. 2006;19:388-95.
Iacobellis G, Sharma AM. Adiposity of the heart. Ann Intern Med. 2006;145:554-5
Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM, Jordan J. Retinolbinding protein 4 in human obesity. Diabetes. 2006;55:2805-10
Sharma AM, Iacobellis G. Treatment of obesity: a challenging task. Contrib Neprhol
2006;151:212-20.
Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH,
Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human invitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J
Hypertens. 2006;24:1809-1816.
Merchant A, Yusuf S, Sharma AM. A cardiologist's guide to waist management. Heart.
2006;92:865-6.
Chetty VT, Sharma AM. Can PPARgamma agonists have a role in the management of
obesity-related hypertension? Vasc Pharmacol. 2006;45:46-53.
Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue
promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res. 2006;71:363-73.
Boschmann M, Kreuzberg U, Engeli S, Adams F, Franke G, Klaua S, Scholze J, Weidinger G,
Luft FC, Sharma AM, Jordan J. The effect of oral glucose loads on tissue metabolism during
angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects. Horm
Metab Res. 2006;38:323-9
Boschman M, Adams F, Schaller K, Franke G, Sharma AM, Klaus S, Luft FC, Jordan J.
Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and
obese men. J Hypertens. 2006;24:1173-1180.
Sharma AM. Does obesity limit response to Angiotensin blockade? Curr Hypertens Rep.
2006;8:6-7.
Sharma AM. Telmisartan. The ACE of ARBs? Hypertension. 2006;47:822-3.
Sharma AM. The obese patient with diabetes mellitus: from research targets to treatment
options. Am J Med. 2006;119(5 Suppl 1):S17-23.
Klipstein-Grobusch K, Mohlig M, Spranger J, Hoffmann K, Rodrigues FU, Sharma AM, Klaus
S, Pfeiffer AF, Boeing H. Interleukin-6 g.-174G>C Promoter Polymorphism Is Associated with
Obesity in the EPIC-Potsdam Study. Obes Res. 2006;14:14-8.
Janke J, Engeli S, Gorzelniak K, Feldpausch M, Heintze U, Bohnke J, Wellner M, Herse F,
Lassalle P, Luft FC, Sharma AM.Adipose tissue and circulating endothelial cell specific
molecule-1 in human obesity. Horm Metab Res. 2006;38:28-33.
Deter HC, Micus C, Wagner M, Sharma AM, Buchholz K.Salt sensitivity, anxiety, and
irritability predict blood pressure increase over five years in healthy males. Clin Exp
Hypertens. 2006;28:17-27.
Sharma AM, Bramlage P, Kirch W. Antihypertensive effect of irbesartan and predictors of
response in obesity-associated hypertension. Clin Drug Invest 2005;25: 765-776.
Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt
Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS;
INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000
participants from 52 countries: a case-control study. Lancet. 2005;366:1640-9.
Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, Kreuzberg
U.Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive
patients. J Hypertens. 2005;23:2313-2318.
Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and
clinical relationships with the heart. Nat Clin Pract Cardiovasc Med. 2005;2:536-43.
Gao YJ, Zeng ZH, Teoh K, Sharma AM, Abouzahr L, Cybulsky I, Lamy A, Semelhago L, Lee
RM.Perivascular adipose tissue modulates vascular function in the human internal thoracic
artery. J Thorac Cardiovasc Surg. 2005;130:1130-6.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J,
Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in
human obesity. Diabetes. 2005;54:2838-43.
Dentali F, Sharma AM, Douketis JD. Management of Hypertension in Overweight and Obese
Patients: A Practical Guide for Clinicians. Curr Hypertens Rep. 2005;7:330-336.
Boschmann M, Engeli S, Adams F, Franke G, Luft FC, Sharma AM, Jordan J. Influences of
AT1 Receptor Blockade on Tissue Metabolism in Obese Men. Am J Physiol Regul Integr
Comp Physiol. 2005 Aug 18;290:R219-23.
Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and
potential benefits of weight reduction. Semin Vasc Med. 2005;5:25-33.
Sharma AM, Bramlage P, Kirch W. Good blood pressure control even in overweight patients
MMW Fortschr Med. 2005;147:48.
Arya M. Sharma, MD/PhD
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
Page 6
Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical
effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients-sibutramine and blood pressure. Clin Auton Res 2005;15:200-6.
Sharma AM, Tarnopolsky MA. Regulating adiponectin: of flax and flux. Diabetologia 2005;
48:1035-7
Boschmann M, Engeli S, Adams F, Gorzelniak K, Franke G, Klaua S, Kreuzberg U, Luedtke S,
Kettritz R, Sharma AM, Luft FC, Jordan J. Adipose Tissue Metabolism and CD11b Expression
on Monocytes in Obese Hypertensives. Hypertension. 2005;46:130-6
Sharma AM, Chetty VT. Obesity, hypertension and insulin resistance. Acta Diabetol. 2005
Apr;42 Suppl 1: S3-8.
Sharma AM, Hollander A, Koster J; Efficacy and Safety in Patients with Renal Impairment;
treated with Telmisartan (ESPRIT) Study Group.Telmisartan in patients with mild/moderate
hypertension and chronic kidney disease. Clin Nephrol. 2005;63:250-7.
Sharma AM, Engeli S, Luft FC. The Third International Symposium on Obesity and
Hypertension ISOH'03: 'Genetics and Molecular Mechanisms' (October 23-25, 2003, Berlin
Germany). Int J Obes Relat Metab Disord. 2005;29:727-34.
Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM.Influence of Sibutramine on
blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord.
2005;29:509-16.
Sharma AM, Chetty VT.Weight cycling and hypertension. Curr Hypertens Rep. 2005;7:910
Sharma AM. Managing weighty issues on lean evidence: the challenges of bariatric medicine.
CMAJ. 2005;172:30-1.
Shubair M, Kodis J, McKelvie RS, Arthur HM, Sharma AM. Metabolic profiles and exercise
capacity outcomes: their relationship to overweight and obesity in a Canadian cardiac
rehabilitation setting. J Cardiopul Rehab. 2004;24: 405-13.
Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight
Loss and the Renin-Angiotensin-Aldosterone System. Hypertension. 2005;45:356-62.
Beige J, Bellmann A, Sharma AM, Gessner R. Ethnic origin determines the impact of genetic
variants in dopamine receptor gene (DRD1) concerning essential hypertension. Am J
Hypertens. 2004;17:1184-1187.
Sharma AM. Systolic hypertension in elderly persons. JAMA. 2004;292:2465-6.
Sokar-Todd HB, Sharma AM. Obesity research in Canada: Literature overview of the last 3
decades. Obes Res 2004;10:1547-1553.
Sharma AM. Bariatric medicine with surgery is like nephrology without dialysis. Obes Surg
2004; 14: 1145-47.
Bramlage P, Pittrow D, Wittchen HU, Kirch W, Bohler S, Lehnert H, Hofler M, Unger T,
Sharma AM. Hypertension in Overweight and Obese Primary Care Patients is Highly
Prevalent and Poorly Controlled. Am J Hypertens 2004:904-910.
Bramlage P, Wittchen HU, Pittrow D, Kirch W, Krause P, Lehnert H, Unger T, Hofler M,
Kupper B, Dahm S, Bohler S, Sharma AM. Recognition and management of overweight and
obesity in primary care in Germany. Int J Obes Relat Metab Disord 2004;28:1299-308.
Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese
patients with the metabolic syndrome: a postmarketing surveillance study. J Hum
Hypertens 2004;18:669-75.
Sharma AM. Mediastinal Fat, Insulin Resistance and Hypertension. Hypertension
2004;44:117-8.
Stefan Engeli, Jürgen Janke, Kerstin Gorzelniak, Jana Böhnke, Nila Ghose, Carsten
Lindschau, Friedrich C. Luft, and Arya M. Sharma. Regulation of the nitric oxide system in
human adipose tissue J Lipid Res. 2004;45(9):1640-8.
Douketis J, Sharma AM. The authors' reply. Drugs 2004;64:1264-5.
Sharma AM. Is There a Rationale for Angiotensin Blockade in the Management of Obesity
Hypertension? Hypertension 2004;44:12-9.
Steckelings UM, Stoppelhaar M, Sharma AM, Wittchen HU, Krause P, Kupper B,
Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Hofler M, Pfister H,
Unger T; HYDRA Study Group. HYDRA: possible determinants of unsatisfactory hypertension
control in German primary care patients. Blood Press. 2004;13:80-8.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM.
Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and
weight loss. Obes Res 2004;12:9-17.
Bramlage P, Sharma AM, Kirch W. Arterial hypertension in obese patients. Rationale for a
prospective medical care study in the family doctor's practice MMW Fortschr Med.
2004;146 Suppl 2:45-50.
Arya M. Sharma, MD/PhD
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
Page 7
Bramlage P, Sharma AM, Kirch W. Arterial hypertension in adipose patients. Rationale for a
prospective medical care study in the family physician practice MMW Fortschr Med.
2004;146:47.
Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Krause
P, Hofler M, Pfister H, Bramlage P, Unger T; HYDRA Study Group. High prevalence and poor
control of hypertension in primary care: cross-sectional study. J Hypertens. 2004;22:47986.
Douketis JD, Sharma AM. The management of hypertension in the overweight and obese
patient: is weight reduction sufficient? Drugs. 2004;64:795-803.
Pittrow D, Kirch W, Bramlage P, Lehnert H, Hofler M, Unger T, Sharma AM, Wittchen HU.
Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol.
2004;60:135-42.
Boschman M, Steiniger J, Hille U, Tank J, Adam F, Sharma AM, Klaus S, Luft FC, Jordan J.
Water-induced thermogenesis. J Clin Endocrinol Metab 2003;88:6015-9.
Tank J, Jordan J, Diedrich A, Schroeder C, Furlan R, Sharma AM, Luft FC, Brabant G. Bound
leptin and sympathetic outflow in non-obese men. J Clin Endocrinol Metab 2003;
88:4955-9.
Sharma AM. Obesity and Cardiovascular Risk. Growth Horm IGF Res. 2003;13 Suppl:S107.
Buchholz K, Schachinger H, Wagner M, Sharma AM, Deter HC. Reduced Vagal Activity in
Salt-Sensitive Subjects During Mental Challenge. Am J Hypertens 2003;16:531-6.
Tank J, Schroeder C, Stoffels M, Diedrich A, Sharma AM, Luft FC, Jordan J. Pressor Effect of
Water Drinking in Tetraplegic Patients May be a Spinal Reflex. Hypertension
2003;88:4955-9.
Wittchen HU, Krause P, Höfler M, Pfister H, Küpper B, Pittrow D, Bramlage P, Unger T,
Sharma AM, Ritz E, Göke B, Lehnert H, Tschöpe D, Kirch W. Aim, design and methods for
the hypertension and diabetes screening and awareness (HYDRA study). Fortschritte der
Medizin 2003;121 Suppl 1:19-27.
Pischon T, Sharma AM, Mansmann U, Agrawal R. Effect of forced titration of nebivolol on
response in obese hypertensive. Am J Hypertens 2003;16:98-100.
Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, Stoffels M, Sharma AM,
Luft FC, Klaus S. Tissue-Specific Response to Interstitial Angiotensin II in Humans.
Hypertension 2003;41:37-41.
Sharma AM. Effects of exercise on plasma lipoproteins. N Engl J Med 2003 10;348:1494.
Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F,
Sharma AM. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic
syndrome? Int J Biochem Cell Biol. 2003;35:807-25
Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Mohlig M, Pfeiffer AF,
Luft FC, Sharma AM. Association Between Adiponectin and Mediators of Inflammation in
Obese Women. Diabetes 2003;52:942-947
Peters H, Ruckert M, Gaedeke J, Liefeldt L, Ketteler M, Sharma AM, Neumayer HH.
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits
transforming growth factor-beta overexpression in acute normotensive anti-thy1
glomerulonephritis. J Hypertens 2003;21:771-80
Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, Stoffels M, Sharma AM,
Luft FC, Klaus S. Tissue-Specific Response to Interstitial Angiotensin II in Humans.
Hypertension 2003;41:37-41.
Wittchen HU, Krause P, Hofler M, Pfister H, Ritz E, Goke B, Lehnert H, Tschope D, Kirch W,
Pittrow D, Sharma AM, Bramlage P, Kupper B, Unger T. Hypertension, diabetes mellitus and
comorbidity in primary care Fortschr Med Orig. 2003 ;121 Suppl 1:19-27.
Krause P, Wittchen HU, Kupper B, Pittrow D, Unger T, Sharma AM, Ritz E, Goke B, Lehnert
H, Tschope D, Kirch W, Pfister H, Bramlage P, Hofler M. Management of diabetes and
hypertension: how do primary care physicians judge their performance? Fortschr Med
Orig. 2003;121 Suppl 1:12-8.
Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J.
Selective impairment in sympathetic vasomotor control with norepinephrine transporter
inhibition. Circulation. 2003;107:2949-54.
Jordan J, Sharma AM. Potential for sibutramine-yohimbine interaction? Lancet.
2003;361:1826.
Wellner M, Herse F, Janke J, Gorzelniak K, Engeli S, Bechart D, Lasalle P, Luft FC, Sharma
AM. Endothelial cell specific molecule-1--a newly identified protein in adipocytes. Horm
Metab Res. 2003;35:217-21.
Beige J, Kreutz R, Tscherkaschina I, Scherer S, Sharma AM, Zidek W, Offerman G. Matrix
analysis for the dissection of interactions of G-Protein beta3 subunit C825T genotype,
allograft function and posttransplant hypertension in kidney transplantation. Am J Kidney
Dis 2002;40:1319-24.
Arya M. Sharma, MD/PhD
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
Page 8
Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab
Disord 2002;26 Suppl 4:S5-7.
Boschmann M, Schroeder C, Christensen NJ, Tank J, Krupp G, Biaggioni I, Klaus S, Sharma
AM, Luft FC, Jordan J. Norepinephrine transporter function and autonomic control of
metabolism. J Clin Endocrinol Metab. 2002;97:5130-7.
Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma
AM, Jordan J. Paradoxial effect of sibutramine on autonomic cardiovascular regulation.
Circulation. 2002;106:2459-65.
Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2
diabetes by formation of fat cells. Hypertension. 2002;40:609-611.
Pischon T, Sharma AM. Optimizing blood pressure control in the obese patient. Curr
Hypertens Rep. 2002;26:358-362.
Busjahn A, Aydin A, Uhlmann R, Krasko C, Bahring S, Szelestei T, Feng Y, Dahm S, Sharma
AM, Luft FC, Lang F.Serum- and glucocorticoid-regulated kinase (SGK1) gene and blood
pressure. Hypertension. 2002;40:256-60.
Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate
in obese patients with hypertension. J Hypertension.2002;20:1873-78.
Pischon T, Sharma AM. Recent developments in the treatment of obesity-related
hypertension. Curr Opin Nephrol Hypertens. 2002;11:497-502.
Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM; Periadvential fat
releases a vascular relaxing factor. FASEB J 2002;16:1057-63
Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Mature adipocytes inhibit in vitro
differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes
2002;51:1699-707
Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM: Hormonal regulation of the human
adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J
Hypertens 2002;20:965-73
Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Resistin expression in human
adipocytes: relationship to adipogenic differentiation and insulin resistance. Obesity
Research 2002;10:1-5
Barta P, Monti J, Maass PG, gorzelniak K, Mueller DN, Dechend R, Luft FC, Hübner N,
SharmaAM: A gene expression analysis in rat kidney following high and low salt intake. J
Hypertension 2002;20:1115-20
Gollasch M, Tank J, Luft FC, Jordan J, Maass P, Krasko C, Sharma AM, Busjahn A, Bähring S:
The BK channel ß1 subunit gene is associated with human baroreflex and blood pressure
regulation. J Hypertesion 2002;20:927-933
Jordan J, Tank J, Hohenbleicher H, Toka H, Schröder C, Sharma AM, Luft FC: Heterogeneity
of autonomic regulation in hypertension with neurovascular contact. J Hypertension
2002;20:701-706
Jordan J, Tank J, Shannon JR, Diedrich A, Lipp A, Schroder C, Arnold G, Sharma AM,
Biaggioni I, Robertson D, Luft FC. Baroreflex buffering and susceptibility to vasoactive drugs.
Circulation 2002;105:1459-64
Schröder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J:
Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance.
Circulation 2002;105:347-53
Engeli S, Sharma AM. Emerging concepts in the pathophysiology and treatment of obesityassociated hypertension. Curr Opin Cardiol. 2002 ;17:355-9.
Jordan J, Lipp A, Tank J, Schroder C, Stoffels M, Franke G, Diedrich A, Arnold G, Goldstein
DS, Sharma AM, Luft FC. Catechol-o-methyltransferase and blood pressure in humans.
Circulation. 2002;106:460-5.
Sharma AM, Rossner S. Who cares about the obese hypertensive patient? J Intern Med.
2002;251:369-71.
Hamann A, Sharma AM. Genetics of obesity and obesity-related hypertension. Semin
Nephrol. 2002;22:100-4.
Sharma AM, Engeli S. Managing big issues on lean evidence: treating obesity hypertension.
Nephrol Dial Transplant. 2002;17:353-5.
Hohenbleicher H, Schmitz SA, Koennecke HC, Offermann J, Offermann R, Wolf KJ, Distler A,
Sharma AM. Neurovascular contact and blood pressure response in young, healthy,
normotensive men. Am J Hypertens. 2002;15:119-24.
Kunz I, Schorr U, Rommling K, Klaus S, Sharma AM. Habitual fat intake and basal fat
oxidation in obese and non-obese Caucasians. Int J Obes Relat Metab Disord.
2002;26:150-6.
Schorr U, Schultz C, Sharma AM. Plasma-renin response to isotonic volume contraction in
young salt-sensitive normotensive men. Am J Hypertens. 2002 ;15 :48-52.
Arya M. Sharma, MD/PhD
Page 9
105. Sharma AM. Long-term weight loss and changes in blood pressure. Curr Hypertens Rep.
2002 ;4 :11-2.
106. Boschmann M, Ringel J, Klaus S, Sharma AM: Metabolic and hemodynamic response of
adipose tissue to angiotensin II Obesity Res 2001;9:486-491
107. Brand E, Schorr U, Kunz I, Kertmen E, Ringel J, Distler A, Sharma AM: Tumor necrosis
factor-a-308 G/A polymorphism in obese caucasians Int J Obesity 2001;25:581-585
108. Tank J, Diedrich A, Schroeder C, Stoffels M, Franke G, Sharma AM, Luft FC, Jordan J. Limited
effect of systemic beta-blockade on sympathetic outflow. Hypertension 2001; 38:13771381
109. Monti J, Gross V, Luft FC, Milia AF, Schulz H, Dietz R, Sharma AM, Huebner N: Expression
analysis with oligonucleotide microarrays in mice lacking bradykinin type 2 receptors.
Hypertension 2001;38:E1-3
110. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC: Beta adrenoceptor antagonists and weight
gain: a systematic analysis Hypertension 2001;37:250-254
111. Sharma AM. Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat
Metab Disord. 2001;25 Suppl 4:S20-3.
112. Pischon T, Sharma AM. Lowering blood pressure in obese hypertensive patients. Which
antihypertensive drugs are suitable. MMW Fortschr Med. 2001;143:34-8.
113. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of
weight gain. Obes Rev. 2001;2:275-80.
114. Buchholz K, Schachinger H, Wagner M, Schorr U, Sharma AM, Deter HC. Enhanced affective
startle modulation in salt-sensitive subjects. Hypertension. 2001;38:1325-9.
115. 24: Sharma AM, Grassi G. Obesity and hypertension: cause or consequence? J Hypertens.
2001;19:2125-6.
116. Gorzelniak K, Janke J, Engeli S, Sharma AM. Validation of endogenous controls for gene
expression studies in human adipocytes and preadipocytes. Horm Metab Res.
2001;33:625-7.
117. Sharma AM. Beta blockers in therapy of hypertension. For obese patients only the second
choice? MMW Fortschr Med. 2001;143:10.
118. Scholze J, Sharma AM. Treatment of hypertension in obesity Herz. 2001;26:209-21.
119. Sharma AM. Obesity: a weighty problem for cardiovascular medicine Herz. 2001;26:169.
120. Janke J, Engeli S, Gorzelniak K, Sharma AM. Extraction of total RNA from adipocytes. Horm
Metab Res. 2001;33:213-5.
121. Deter HC, Buchholz K, Schorr U, Mathiak K, Sharma AM. Salt-sensitivity and other predictors
of stress-related cardiovascular reactivity in healthy young males. Clin Exp Hypertens.
2001;23:213-25.
122. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related
hypertension: where is the evidence? J Hypertens. 2001;19:667-74.
123. Sharma AM, Homuth V, Luft FC. Hormone replacement therapy and blood pressure in
normotensive and hypertensive women. Nephrol Dial Transplant. 2001;16:888-90.
124. Sharma AM, Despres JP. Obesity: the dire consequences of a genetic program for survival? J
Mol Med. 2001;79:6-7.
125. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesityassociated hypertension. J Mol Med. 2001;79:21-9.
126. Brand E, Schorr U, Kunz I, Kertmen E, Ringel J, Distler A, Sharma AM. Tumor necrosis
factor-alpha--308 G/A polymorphism in obese Caucasians. Int J Obes Relat Metab Disord.
2001;25:581-5.
127. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced
hypertension: role of adipose tissue. Curr Hypertens Rep. 2001;3:152-6.
128. Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and
disease. Horm Metab Res. 2000;32:485-99.
129. Pischon T, Sharma AM. Obesity as a risk factor in renal transplant patients. Nephrol Dial
Transplant. 2001;16:14-7.
130. Hohenbleicher H, Schmitz SA, Koennecke HC, Offermann R, Offermann J, Zeytountchian H,
Wolf KJ, Distler A, Sharma AM. Neurovascular Contact of Cranial Nerve IX and X Root-Entry
Zone in Hypertensive Patients. Hypertension. 2001;37:176-181.
131. Kunz I, Schorr U, Klaus S, Sharma AM: Resting metabolic rate and substrate utilization in
obesity hypertension. Hypertension 2000;36:26-32
132. Kunz I, Klaus S, Kallies B, 'Schorr U, Sharma AM: Kinetic analysis of the thermic effect of
food and its relationship to body composition in humans Metabolism 2000;49:1340-1345
133. Ringel J, Kreutz R, Distler A, Sharma AM: the Trp64Arg Polymorphism of the ß3-Adrenergic
Receptor Gene is Associated with Hypertension in Men with Type 2 Diabetes Mellitus Am J
Hypertens 2000;13;1027-1031
Arya M. Sharma, MD/PhD
Page 10
134. Schorr U, Sharma AM. Salt intake and left ventricular work load. J Hypertens.
2000;18:1721-4.
135. Beige J, Sone J, Sharma AM, Rudwaleit M, Offermann G, Distler A, Preuschof L.
Computational analysis of blood volume curves and risk of intradialytic morbid events in
hemodialysis. Kidney Int. 2000;58:1805-9.
136. Ringel J, Kreutz R, Distler A, Sharma AM. The Trp64Arg polymorphism of the beta3adrenergic receptor gene is associated with hypertension in men with type 2 diabetes
mellitus. Am J Hypertens. 2000;13:1027-31.
137. Beige J, Ringel J, Distler A, Sharma AM. G-protein beta(3)-subunit C825T genotype and
nephropathy in diabetes mellitus. Nephrol Dial Transplant. 2000;15:1384-7.
138. Wirth A, Sharma AM, Schunkert H. Cardiomyopathy in obesity--a disease entity? Dtsch Med
Wochenschr. 2000;125:944-9.
139. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM. G-protein beta3 subunit 825T allele
and response to dietary salt in normotensive men. J Hypertens. 2000;18:855-9.
140. Sharma AM, Jeunemaitre X. The future of genetic association studies in hypertension:
improving the signal-to-noise ratio. J Hypertens. 2000;18:811-4.
141. Sharma AM, Pischon T, Engeli S. Effect of ramipril on cardiovascular events in high-risk
patients. N Engl J Med. 2000;343:65
142. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue reninangiotensin system. Hypertension. 2000;35:1270-7.
143. Sharma AM. Association studies of genetic polymorphisms and complex disease. Lancet.
2000;355:1277.
144. Moeller T, Buhl M, Schorr U, Distler A, Sharma AM. Salt intake and hypertension in renal
transplant patients. Clin Nephrol. 2000;53:159-63.
145. Brand E, Ringel J, Sharma AM. Role of the angiotensinogen gene for essential hypertension
Herz. 2000;25:15-25.
146. Chung O, Hinder M, Sharma AM, Bonner G, Middeke M, Platon J, Unger T. Comparison of the
efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker
mibefradil (50-100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol.
2000;14:31-41.
147. Sharma AM, Distler A, Hauner H. International symposium on obesity and hypertension
genetics and molecular mechanisms. Genetics and molecular mechanisms. Kidney Blood
Press Res. 2000;23:49-72.
148. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM: Co-expression of reninangiotensin system genes in human adipose tissue J Hypertens 1999;17:555-60.
149. Koch R, Sharma AM. Obesity and cardiovascular hemodynamic function. Curr Hypertens
Rep. 1999;1:127-30.
150. Sharma AM. Specialize before you retire. Natl Med J India. 1999;12:188.
151. Brand E, Schorr U, Ringel J, Beige J, Distler A, Sharma AM. Aldosterone synthase gene
(CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial
(BeSST). J Hypertens. 1999;17:1563-7.
152. Sharma AM, Moeller T, Engeli S. Hypertension in obesity: its epidemiology, physiopathology
and treatment efforts. Dtsch Med Wochenschr. 1999;124:1337-41.
153. Schmitz SA, Hohenbleicher H, Koennecke HC, Offermann R, Offermann J, Branding G, Wolf
KJ, Distler A, Sharma AM. Neurogenic hypertension. A new MRI protocol for the evaluation of
neurovascular compression of the cranial nerves IX and X root-entry zone. Invest Radiol.
1999;34:774-80.
154. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM. Molecular
basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2.
J Clin Endocrinol Metab. 1999;84:3745-9.
155. Buchholz K, Schorr U, Turan S, Sharma AM, Deter HC. Emotional irritability and anxiety in
salt-sensitive persons at risk for essential hypertension Psychother Psychosom Med
Psychol. 1999;49:284-9.
156. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, Crookes R, Du P Heyns A,
Epplen JT, Fridey J, Freedman BI, Muller N, Stolke D, Sharma AM, Al Moutaery K, GrosseWilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J,
Wang Y, Rosskopf D, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T
allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J
Am Soc Nephrol. 1999;10:1921-30.
157. Beige J, Engeli S, Ringel J, Offermann G, Distler A, Sharma AM. Donor G protein beta3
subunit 825TT genotype is associated with reduced kidney allograft survival. J Am Soc
Nephrol. 1999;10:1717-21.
158. Sharma AM. Who should pay for anti-obesity drugs? Natl Med J India. 1999;12:79.
159. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM. Angiotensinogen M235T variant and
salt sensitivity in young normotensiveCaucasians. J Hypertens. 1999;17:475-9.
Arya M. Sharma, MD/PhD
Page 11
160. Beige J, Hohenbleicher H, Distler A, Sharma AM. G-Protein beta3 subunit C825T variant and
ambulatory blood pressure in essential hypertension. Hypertension. 1999;33:1049-51.
161. Beige J, Sharma AM, Distler A, Offermann G, Preuschof L. Monitoring dialysis efficacy by
comparing delivered and predicted Kt/V. Nephrol Dial Transplant. 1999;14:683-7.
162. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome
proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res
Commun. 1999;254:450-3.
163. Sharma AM, Maier T, Jung C. Angiotensin II receptor blockade and renal protection. Basic
Res Cardiol 1998;93 Suppl 2: 120-4.
164. Beige J, Offermann G, Distler A, Sharma AM: Angiotensin-converting-enzyme
insertion/deletion genotype and long-term renal allograft survival. Nephrol Dial
Transplant. 1998;13:735-8.
165. Brand E, Chatelain N, Keavney B, Caulfied M, Citterio L, Connell J, Grobbee D, Schmidt S,
Schunkert H, Schuster H, Sharma AM, Soubrier F. Evaluation of the angiotensinogen locus in
human essential hypertension: a European study. Hypertension 1998;31:725-9.
166. Sharma AM. Genetics of salt sensitivity: In which patients is salt restriction effective?
Fortschr Med 1998;116:39.
167. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann
HE, Jakobs KH, Horsthemke B. Association of a human G-protein ß3 subunit variant with
hypertension. Nature Genetics 1998;18:45-8.
168. Krause R, Burhing M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood
pressure. Lancet 1998;12:571-2.
169. Gorzelniak K, Engeli S, Sharma AM: Standardizing the counting of adipocytes in cell culture.
BioTechniques 1998;24:536-8
170. Sharma AM. Fraud in science. Natl Med J India 1998;11:188-9.
171. Beige J, Sharma AM: Valsartan zur Behandlung der Herzinsuffizienz bei einer 73 jährigen
Patientin mit terminaler Niereninsuffizienz. Herz Kreisl 1998;30:273-4
172. Sharma AM, Beige J, Distler A. Role of genetic variants of the renin-angiotensin system in
chronic renal allograft injury. Kidney Int 1998;53:1461-5.
173. Sharma AM. The thrifty-genotype hypothesis and its implications for the study of complex
genetic disorders in man. J Mol Med 1998;76;568-71.
174. Sharma AM. Studying in Germany: a harrowing prospect. Natl Med J India 1998;11:89.
175. Liangos O, Kreutz R, Beige J, Offermann G, Distler A, Sharma AM: Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. Nephrol
Dial Transplant 1998;13:2351-4.
176. Schorr U, Ringel J, Stumpe KO, Distler A, Sharma AM: Non-pharmacological treatment of
hypertension: a survey of 2150 general practitioners and internists. J Hum Hypertens
1998;12:571-572.
177. Kunz R, Bork JP, Fritsche L, Ringel R, Sharma AM: Angiotensin-converting-enzymeinsertion/deletion polymorphism and diabetic nephropathy: a methodological appraisal and
systematic review. J Am Soc Nephrol 1998;9:1653-63.
178. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between
angiotensinogen, leptin, and blood pressure in young normotensive men. J Hypertension
1998;16:1475-80.
179. Peterman A, Offermann G, Distler A, Sharma AM: Familial hemolytic-uremic syndrome in
three generations: a case report and brief review of the literature. Am J Kidney Dis
1998;32:1063-7.
180. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM: Association between the angiotensinogen
235T-Variant and essential hypertension in Caucasians: a systematic review and
methodological appraisal. Hypertension. 1997;30:1331-7.
181. Schmidt S, Beige J, Walla-Friedel M, Michel M, Sharma AM, Ritz E: A polymorphism in the
gene for the angiotensin II type 1 receptor is not associated with hypertension. J
Hypertension. 1997;15:1385-8.
182. Hohenbleicher H, Klosterman F, Schorr U, Seyfert S, Persson PB, Sharma AM: Identification
of a renin threshold and its relationship to salt intake in a patient with pure autonomic
failure. Hypertension. 1997;30:1068-71.
183. Beige J, Ringel J, Hohenbleicher H, Rubattu S, Kreutz R, Sharma AM. HpaII-polymorphism of
the atrial-natriuretic-peptide gene and essential hypertension in whites. Am J Hypertens
1997;10:1316-8.
184. Sharma AM, Schorr U. Dietary patterns and blood pressure. N Engl J Med 1997; 337:637;
discussion 637-8.
185. Schorr U, Turan S, Distler A, Sharma AM. Relationship between ambulatory and resting
blood pressure responses to dietary salt restriction in normotensive men. J Hypertens
1997;15:845-9.
Arya M. Sharma, MD/PhD
Page 12
186. Beige J, Scherer S, Weber A, Engeli S, Offermann G, Opelz G, Distler A, Sharma AM:
Angiotensin-converting-enzyme genotype and renal allograft survival. J Am Soc Nephrol
1997;8:1319-23.
187. Deter HC, Buchholz K, Schorr U, Schachinger H, Turan S, Sharma AM. Psychophysiological
reactivity of salt-sensitive normotensive subjects. J Hypertens. 1997;15:839-44.
188. Schorr U, Beige J, Ringel J, Turan S, Kreutz R, Distler A, Sharma AM. Hpa II polymorphism
of the atrial natriuretic peptide gene and the blood pressure response to salt intake in
normotensive men. J Hypertens. 1997;15:715-8.
189. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, GimenezRoqueplo AP, Hata A, Corvol P, Lalouel JM. Haplotypes of angiotensinogen in essential
hypertension. Am J Hum Genet. 1997;60:1448-60.
190. Beige J, Zilch O, Hohenbleicher H, Ringel J, Kunz R, Distler A, Sharma AM. Genetic variants
of the renin-angiotensin system and ambulatory blood pressure in essential hypertension. J
Hypertens. 1997;15:503-8.
191. Sharma AM. Clinical versus experimental utility of salt-sensitivity testing. J Hypertens.
1997;15:457-8.
192. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig
EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM. A nucleotide substitution in the
promoter of human angiotensinogen is associated with essential hypertension and affects
basal transcription in vitro. J Clin Invest. 1997;99:1786-97.
193. Ringel J, Beige J, Kunz R, Distler A, Sharma AM. Genetic variants of the renin-angiotensin
system, diabetic nephropathy and hypertension. Diabetologia. 1997;40:193-9.
194. Beige J, Weber A, Engeli S, Offermann G, Distler A, Sharma AM. Angiotensinogen-M235T
genotype and post-transplant hypertension. Nephrol Dial Transplant. 1996;11:1538-41.
195. Sharma AM. Salt sensitivity as a phenotype for genetic studies of human hypertension.
Nephrol Dial Transplant. 1996;11:927-9.
196. Schorr U, Distler A, Sharma AM. Effect of sodium chloride- and sodium bicarbonate-rich
mineral water on blood pressure and metabolic parameters in elderly normotensive
individuals: a randomized double-blind crossover trial. J Hypertens. 1996;14:131-5.
197. Sharma AM, Schorr U. Salt sensitivity and insulin resistance: Is there a link? Blood Press
Suppl. 1996;1:59-63.
198. Hunt SC, Williams CS, Sharma AM, Inoue I, Williams RR, Lalouel JM. Lack of linkage between
the endothelial nitric oxide synthase gene and hypertension. J Hum Hypertens.
1996;10:27-30.
199. Sharma AM. ...and salt resistance. Nat Med. 1996;2:3-4.
200. Sharma AM. Renal tubular dysfunction and acidosis. Nephrol Dial Transplant.
1995;10:1544-45.
201. Schmidt S, Sharma AM, Zilch O, Beige J, Walla-Friedel M, Ganten D, Distler A, Ritz E.
Association of M235T variant of the angiotensinogen gene with familial hypertension of early
onset. Nephrol Dial Transplant. 1995;10:1145-8.
202. Sharma AM, Schorr U, Cetto C, Distler A. Dietary v intravenous salt loading for the
assessment of salt sensitivity in normotensive men. Am J Hypertens. 1994;7:1070-5.
203. Sharma AM, Distler A, Luft FC. Research strategies in the genetics of high blood pressure.
Dtsch Med Wochenschr. 1994;119:742-6.
204. Sharma AM, Distler A. Acid-base abnormalities in hypertension. Am J Med Sci. 1994;307
Suppl 1:S112-5.
205. Sharma AM, Cetto C, Schorr U, Spies KP, Distler A. Renal acid-base excretion in
normotensive salt-sensitive humans. Hypertension. 1993;22:884-90.
206. Sharma AM, Schorr U, Thiede HM, Distler A. Effect of dietary salt restriction on urinary
serotonin and 5-hydroxyindoleacetic acid excretion in man. J Hypertens. 1993 ;11 :1381-6.
207. Luft FC, Sharma AM. Identifying the genetic determinants of hypertension. Clin Investig.
1993;71:871-3.
208. Sharma AM, Schorr U, Oelkers W, Distler A. Effects of sodium salts on plasma renin activity
and norepinephrine response to orthostasis in salt-sensitive normotensive subjects. Am J
Hypertens. 1993;6:780-5.
209. Batlle DC, Sharma AM, Alsheikha MW, Sobrero M, Saleh A, Gutterman C. Renal acid
excretion and intracellular pH in salt-sensitive genetic hypertension. J Clin Invest.
1993;91:2178-84.
210. Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive
subjects. Hypertension. 1993;21:273-9.
211. Sharma AM, Schattenfroh S, Thiede HM, Oelkers W, Distler A. Effects of sodium salts on
pressor reactivity in salt-sensitive men. Hypertension. 1992;19:541-8.
212. Sharma AM. Effects of nonpharmacological intervention on insulin sensitivity. J Cardiovasc
Pharmacol. 1992;20 Suppl 11:S27-34.
Arya M. Sharma, MD/PhD
Page 13
213. Sharma AM, Keller F. Complete anuria in unilateral renal artery obstruction and ischemic
nephropathy. Dtsch Med Wochenschr. 1991;116:1333.
214. Sharma AM, Ruland K, Spies KP, Distler A. Salt sensitivity in young normotensive subjects is
associated with a hyperinsulinemic response to oral glucose. J Hypertens. 1991;9:329-35.
215. Sharma AM, Distler A. Abnormal acid-base regulation in salt-sensitive normotensive man.
Klin Wochenschr. 1991;69 Suppl 25:41-4.
216. Sharma AM, Thiede HM, Keller F. Somatostatin-induced hyperkalemia in a patient on
maintenance hemodialysis. Nephron. 1991;59:445-8.
217. Sharma AM, Kribben A, Schattenfroh S, Cetto C, Distler A. Salt sensitivity in humans is
associated with abnormal acid-base regulation. Hypertension. 1990;16:407-13.
218. Sharma AM, Arntz HR, Kribben A, Schattenfroh S, Distler A. Dietary sodium restriction:
adverse effect on plasma lipids. Klin Wochenschr. 1990;68:664-8.
219. Wenzel-Seifert K, Sharma AM, Keller F. Repeated dialysis anaphylaxia. Nephrol Dial
Transplant. 1990;5:821-4.
220. Sharma AM, Schattenfroh S, Kribben A, Distler A. Reliability of salt-sensitivity testing in
normotensive subjects. Klin Wochenschr. 1989;67:632-4.
221. Sharma AM, Keller F, Boeckh M, Heitz J, Borner K. Quinine dosage in severe malaria with
renal failure necessitating haemodialysis. Eur J Clin Pharmacol. 1989;36:535-6.
222. Philipp T, Sharma AM, Thiede HM, Kribben A. Sympathetic nervous activity and
noradrenaline reactivity during Angiotensin converting enzyme inhibition. Am J Cardiol.
1987;59:55D-59D.
BOOK CHAPTERS
1.
Sharma AM, Iacobellis G (2006). Treatment of Obesity: A Challenging Task. Wolf G (ed):
Obesity and the Kidney. Contrib Nephrol. Basel, Karger, 2006, vol 151, pp 212-220.
2.
Pischon T, Douketis JD and Sharma AM (2004). Weight Loss and Cardiovascular Risk
Factors. In K. Hofbauer, U. Keller, O. Boss O (Eds.), Pharmacotherapy of Obesity. Boca
Raton: CRC Press.
3.
Sharma AM (2002). Obesity. In S. Yusuf, JA Cairns, AJ Camm, EL Fallen, BJ Gersh (Eds.),
Evidence Based Cardiology. London: BMJ Publishing Group London.
4.
Sharma AM und Schorr U (2001). Hypertension as a risk factor for coronary artery disease:
a global perspective. In Rao GHR (Ed.), Coronary artery disease in South Asians. New
Delhi: JAYPEE publishers.
5.
Sharma AM (1999). Genetics of essential hypertension. In Imura HM, Kasuga M, Nakao K
(Eds.), Common disease: genetics and pthogenetic aspects of multifactorial
diseases. Elsevier Science BV
RECENT ACCEPTED ABSTRACTS
1. van Gaal L, Caterson I, Coutinho W, Finer N, Maggionie AP, Sharma AM, Torp-Pedersen C,
James WPT, on the behalf of the SCOUT Investigators. Key Findings of a 6-week Treatment
Period with Sibutramine-An analysis from the Sibutramine Cardiovascular OUTcomes
(SCOUT) Trial. Portuguese Congress of Obesity 2007.
2. Gao YJ, Su L, Lu C, An W, Takemori K, Sharma AM, Lee RMKW. Perivascular adipose tissue
promotes vessel constriction to perivascular nerve activation. 21st Scientific Meeting of
the International Society of Hypertension, Fukuoka, Japan, October 15-19, 2006
3. Iacobellis G, Barbaro G, Pellicelli AM, Grisorio B, Barbarini G, Sharma AM: Echocardiographic
epicardial adipose tissue as a new marker of visceral adiposity and therapeutic target:
evidence drom HIV-infected patients with metabolic syndorme. 13th International
Congress on Obesity, Sydney, Australia, Sept., 2006
4. Sharma AM: The health consequences of obesity are overstated. Obes Rev 2006;7(suppl 2):
12
5. Akhtar M, Gorzelniak G, Basseri S, Ahmed B, Colgan S, Sood SK, Austin RC, Sharma AM:
Unfolded protein response (UPR)/GRP-78 upregulation is required for adipogenic
differentiation of preadipocytes. Obes Rev 2006;7(Suppl. 2):138
6. Gorzelniak K, Ahmed B, Akhtar M, Sharma AM: Angiotensin II-mediated reactive oxygen
species (ROS) production inhibits differentiation of human adipocytes. Obes Rev
2006;7(Suppl. 2):137
7. Shubair MM, Prabhakaran P, Pavlova V, Velianou J, Natarajan M, Sharma AM. Body mass
index and in-hospital outcomes after percutaneous coronary intervention. Annual Scientific
Meeting of the North American Association for the Study of Obesity, Las Vegas,
November 2004.
8. Engeli S, Feldpausch M, Gorzelniak K, Janke J, Luft FC, Sharma AM. The cannabinoid receptor
Type 1 on human adipocytes. Annual Scientific Meeting of the North American
Association for the Study of Obesity, Las Vegas, November 2004.
9. Engeli S, Bohnke J, Janke J, Gorzelniak K, Luft FC, Sharma AM. Weight loss affects the
systemic and adipose-tissue rennin-angiotensin system in obese women. Annual Scientific
Arya M. Sharma, MD/PhD
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Page 14
Meeting of the North American Association for the Study of Obesity, Las Vegas,
November 2004.
Shubair MM, Prabhakaran P, Natarajan MK, Pavlova V, Velianou JL, Sharma AM. Body mass
index and in-hospital outcomes after percutaneous coronary intervention. Canadian
Cardiovascular Congress, Calgary, October 2004.
Engeli S, Bohnke J, Janke J, Gorzelniak K, Luft FC, Sharma AM. Influence of weight reduction
on the systemic and adipose-tissue rennin-angiotensin-aldosterone system in obese women.
58th Annual Fall Conference and Scientific Sessions of the Council for High Blood
Pressure Research, Chicago, October 2004.
Steckelings UM, Stoppelhaar M, Wittchen HU, Sharma AM. HYDRA: Possible Determinants of
Unsatisfactory Hypertension Control in German Primary Care. 14th European Meeting on
Hypertension, Paris, June 2004
Engeli S, Baranov S, Soldatov A, Lehrach H, Luft FC, Sharma AM. Adipose Tissue Gene
Expression Profiling in Human Obesity and Hypertension. 13th European Congress on
Obesity, Prague, May 2004.
Janke J, Engeli S, Gorzelniak K, Feldpausch M, Luft FC, Sharma AM. Adipose and Circulating
ESM-1 in Human Obesity. 13th European Congress on Obesity, Prague, May 2004.
Engeli S, Feldpausch M, Gorzelniak K, Janke J, Luft FC, Sharma AM. Adipose Cannabinoid
Receptor Type 1 in Human Obesity. 13th European Congress on Obesity, Prague, May
2004.
Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of Sibutramine on
Blood Pressure: Evidence from Two Placebo-Controlled Trials with Hypertensive Obese
Patients in Germany. 13th European Congress on Obesity, Prague, May 2004.
Nair P, Radford K, Fanat A, Sharma AM, Cox G. The effect of leptin and adiponectin on human
airway smooth muscle cell migration. European Respiratory Society Annual Congress
2004
Sokar-Todd H, Sharma AM. Obesity Research in Canada: Systematic Review of the Last Three
Decades. Obes Res 2003; 11 (Suppl):A147
Shubair M, Kodis J, McKelvie R, Sharma AM. Prevalence of Overweight and Obesity in a
Canadian Cardiac Rehabilitation Setting. Obes Res 2003;11(Suppl):A128
Sharma AM, Bramlage P, Pittrow D et al. Prevalence of Overweight and Obesity in Primary
Care Patients in Germany. Obes Res 2003;11(Suppl):A127
Sharma AM, Bramlage P, Kirch W et al. High Body Mass Index is Associated with an Increased
Prevalence and Lack of Control of Hypertension. Obes Res 2003;11(Suppl):A123
Sharma A, Pirner M, Hewkin A, Renz C. Effect of Sibutramine Versus Placebo on Blood
Pressure in Randomized, Double-Blind Controlled Trials: A Retrospective Analysis. Obes Res
2003; 11: A110 (Suppl)
Sharma A, Otis J, Killian K. Effects of Obesity on Blood Pressure Responses during Exercise in
Normal Subjects. Obes Res 2003; 11: A85 (Suppl)
Engeli S, Janke J, Gorzelniak K, et al. Regulation of the “Endothelial Specific Molecule-1” in
Human Adipose Tissue. Obe Res 2003; 11: A45 (Suppl)
Engeli S, Baranov S, Soldatov A, Lehrach H, Luft F, Sharma AM. Differential expression of
human adipose-tissue genes in obesity-hypertension using cDNA microarrays. Obes Res
2003; 11: A43 (Suppl)
Jordan J, Tank J, Toka HR, et al. Selective impairment in baroreflex control of vascular tone
and vasopressin release in patients with monogenic hypertension and brachydactyly
Hypertension 2000; 36: 668-668
Buchholz K, Wagner M, Sharma AM, et al. Startle modulation in young males at risk for
hypertension J Psychosom Res 2000; 48:103
Deter HC, Wagner M, Sharma AM, et al. Hostility and anger as predictors of sympathetic
activity in young men at risk for hypertension J Psychosom Res 2000:48:105
Schorr U, Kunz I, Klaus S, et al. Relationship between resting metabolic rate and obesity
hypertension J Hypertens 2000;18(suppl 2):S7
Moeller T, Hardt S, Kunz I, et al. Weight gain with beta-blockers: A systematic review of the
literature J Hypertens 2000;18(suppl 2): S20-S21
Brand E, Ringel J, Distler A, et al. Role of the glucagon receptor gene mutation (Gly40Ser) in
human essential hypertension J Hypertens 2000;18(suppl 2): S115
Ringel J, Brand E, Distler A, et al. Gly(40)Ser missense mutation in the glucagon receptor
gene and diabetes mellitus J Hypertens 2000;18(suppl 2): S115-S116
Buchholz K, Wagner M, Schorr U, et al. Central mechanisms: Do they play a role in the
development of hypertension J Hypertens 2000;18(suppl 2): S137
Sharma AM Genetics of salt sensitivity J Mol Med 2000;78:O21
Staessen JA, Wang JG, Brand E, et al. Association between blood pressure, hypertension and
polymorphisms of the aldosterone synthase and ?-adducin genes in a Belgian population
study J Mol Med 2000;78:O23
Arya M. Sharma, MD/PhD
Page 15
36. Brand E, Kertman E, Schorr U, et al. Role of tumor necrosis factor-alpha G-308A
polymorphism in obesity J Mol Med 2000;78:P4
37. Brand E, Schorr U, Turan S, et al. Role df the aldosterone synthase gene C-344T variant in
salt sensitivity J Mol Med 2000;78:P5
38. Sharma AM, Schorr U, Blaschke K, et al. G-protein beta 3 subunit 825T allele is not
associated with the blood-pressure response to dietary salt in normotensive men
Hypertension 1999 34: 707
39. Ringel J, Brand E, Distler A, et al. Evaluation of the 11 beta-HSD2 gene in diabetes mellitus
Hypertension 1999 34:707
40. Brand E, Schoor U, Turan S, et al. Aldosterone synthase gene C-344T polymorphism and salt
sensitivity in caucasians Hypertension 1999 34:708
41. Sharma AM, Hohenbleicher H, Schmitz SA, et al. Evaluation of neurovascular compression of
the cranial nerves IX and X root-entry zone in hypertensive patients and normotensive
controls Hypertension 1999 34:709-709
42. Engeli S, Ringel J, Distler A, Sharma AM: Pro 12ALA Missense Mutation of the Peroxisome
Proliferator Activated Receptor  and Diabetes Mellitus. Int J Obes 1999;23 (5):S77
43. Kunz I, Schorr U, Sharma AM, Klaus S: Thermic Effect of Food: Influence of Body Fat and Adrenergic Blockade. Int J Obes 1999;23 (5):S91
44. Boschmann M, Ringel J, Klaus S, Sharma AM: Angiotensin II Induced Changes in Blood Flow
and Lipolysis in white Adipose Tissue. Int J Obes 1999;23 (5):S67
45. Hohenbleicher H, Schmitz S, Könnecke C, Offermann R, Offermann J, Wolf KJ, Distler A,
Sharma AM: Neurovascular Compression and Blood Pressure Reactivity in Young Healthy
Normotensive Men. J Hypertens 1999; 17 (S3):S239
46. Maier T, Sarup S, Ringel J, Schorr U, Distler A, Sharma AM: Renal Acid-Base Regulation in
Hypertension and Obesity. J Hypertens 1999; 17 (S3):S36
47. Möller T, Buhl M, Schorr U, Distler A, Sharma AM: Dietary Salt Intake and Hypertension in
Renal Transplant Patients. J Hypertens 1999; 17 (S3):S39
48. Schorr U, Schultz C, Ringel J, Distler A, Sharma AM: Plasma Renin Response to Sodium
Depletion and Salt Sensitivity in Young Normotensive Men. J Hypertens 1999; 17 (S3):S143
49. Ringel J, Kreutz R, Distler A, Sharma AM: The TRP64ARG Polymorphism of the 3-Adrenergic
Receptor Gene in German Patients with Type 2 Diabetes Mellitus and Hypertension. J
Hypertens 1999; 17 (S3):S165
50. Ringel J, Engeli S, Distler A, Sharma AM: Pro 12ALA Missense Mutation of the Peroxisome
Proliferator Activated Receptor , Diabetes Mellitus and Hypertension. J Hypertens 1999; 17
(S3):S165
51. Beige J, Hohenbleicher H, Ringel J, Distler A, Sharma AM: G-Protein 3 Subunit 825 T Allele
and Ambulatory Blood Pressure in Essential Hypertension. J Hypertens 1999; 17 (S3):S170
52. Ferrari P, Lovati E, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM: Molecular Basis of
Human Salt Sensitivity: The Role of the 11 -Hydroxysteroid Dehydrogenase Type 2. J
Hypertens 1999; 17 (S3):S148
53. Chung O, Hinder M, Sharma AM, Bönner G, Middeke M, Platon J, Unger Th: Comparative
Evaluation of the Antihypertensive Efficacy and Tolerability of Mibefradil and Losartan. J
Hypertens 1999; 17 (S3):S223
54. Janke J, Gorzelniak K, Engeli S, Dorbic T, Wittig B, Sharma AM: Transfektion primärer
Präadipozytenkulturen mit dem Ballistomagnetischen Vektor System. 15. Jahrestagung der
Deutschen Adipositas-Gesellschaft, Düsseldorf 16.-18. September 1999
55. Kunz I, Schorr U, Klaus S, Sharma AM: Energiestoffwechsel bei Adipositas-assoziierter
Hypertonie. 15. Jahrestagung der Deutschen Adipositas-Gesellschaft, Düsseldorf 16.18. September 1999
56. Beige J, Engeli S, Ringel J, Offermann G, Distler A, Sharma AM: Donor G-Protein 3 Genotype
is Associated with Kidney Allograft Survival. 30. Kongreß der Gesellschaft für
Nephrologie 18.-21. September 1999
57. Beige J, Sone J, Sharma AM, Rudwaleit M, Preuschof L, Distler A: Computational Analysis of
Blood Volume Curves and Risk of Hemodialysis Comlications. 30. Kongreß der Gesellschaft
für Nephrologie 18.-21. September 1999
58. Beige J, Ringel J, Distler A, Sharma AM: G-Protein 3-Subunit C825T Genotype and VascularRenal Complications in Diabetes Mellitus. 30. Kongreß der Gesellschaft für Nephrologie
18.-21. September 1999
59. Ringel J, Kreutz R, Distler A, Sharma AM: The TRP64ARG Polymorphism of the 3-Adrenergic
Receptor Gene in German Patients with Tpye2 Diabetes Mellitus and Hypertension. 23.
Wissenschaftliche Tagung der Deutschen Liga zur Bekämpfung des hohen
Blutdruckes, 17.-20. November 1999, Karlsruhe
60. Sharma AM. Pathophysiologie der Adipositas-Hypertonie: Bedeutung des Renin-AngiotensionSystems, Virchow-Kolloquium, Berlin, 21.6.2000
Arya M. Sharma, MD/PhD
Page 16
RECENT INVITED PRESENTATIONS (Industry-sponsored where indicated)
International Conferences/Symposia
1. Keynote Lecture, Plenary Session: Biennial Meeting of the South African Hypertension
Society, 26th to 28th May 2007 (DECLINED)
2. Lecture: Plenary Session: Visceral Obesity and Cardiometabolic Risks, 15th European
Congress on Obesity, Budapest, Hungary, April 22-25, 2007
3. Lecture: The Adipocyte as an Endocrine Organ, 1st Portuguese Congress on
Hypertension, Algarve, Portugal, February 8-11, 2007 (DECLINED)
4. Moderator: Round Table on Obesity and Hypertension, 1st Portuguese Congress on
Hypertension, Algarve, Portugal, February 8-11, 2007 (DECLINED)
5. Workshop: The Rationale for angiotensin blockade in the management of obese hypertensives
and Obesity-a challenge and CV risk factor. 21st Scientific Meeting of the International
Society of Hypertension. Fukuoka, Japan, October15-19, 2006.
6. Speaker: Obesity - a challenge and cardiovascular risk factor. 21st Scientific Meeting of
the International Society of Hypertension, Fukuoka, Japan, October 15-19, 2006
7. Lecture: Medical treatment of obesity, 4th Annual World Congress on the Insulin
Resistance Syndrome - Las Vegas,Nevada, October 5-7, 2006 (DECLINED)
8. Lecture: What is new in the pharmacological therapy of visceral obesity? 8th Hong Kong
Diabetes and Cardiovascular Risk Factors - East Meets West Symposium (EmW),
Hong Kong, September 30 – October 1, 2006 (DECLINED)
9. Debate: The Health Consequences of Obesity are Overstated? 10th International Congress
on Obesity, Sydney, Australia, September. 3-8, 2006
10. Chairman: State-of-the Art Lecture: Obesity and the Elderly. 10th International Congress
on Obesity, Sydney, Australia, September. 3-8, 2006
11. Speaker: Obesity and the values of lifestyle modification, A New Dawn in Cardiovascular
Protection, Tokyo, July 27-31, 2006 (Boehringer Ingelheim)
12. Moderator: The ECS and the role of rimonabant in the mamagement of other CMR factors,
1st Rimonabant Forum, Paris, June 23-24, 2006 (Sanofi-Aventis)
13. Facilitator: Rimonabant in obesity, diabetes, dyslipidemia and cardiovascular risk
management guidelines, 1st Rimonabant Forum , Paris, June 23-24, 2006 (Sanofi-Aventis)
14. Lecture: Prevalence and clinical implications of abdominal obesity and associated
cardiometabolic risk factors, Satellite Symposium (Sanofi-Aventis): Abdominal Obesity,
Hypertension and Related Cardiometabolic Risk Factors, XVI European Meeting on
Hypertension, Madrid, June 12-15, 2006
15. Lecture: Renin-angiotensin system and adipose tissue, Topical Workshop: Adipose Tissue and
CV Risk-Mechanisms, XVI European Meeting on Hypertension, Madrid, June 12-15, 2006
16. Chairman: Plenary Session: From Arterial Hypertension to Intra-Abdominal Adiposity, XVI
European Meeting on Hypertension, Madrid, June 12-15, 2006
17. Chairman: First Session of the Working Group on Obesity: Obesity and Hypertension, XVI
European Meeting on Hypertension, Madrid, June 12-15, 2006
18. Lecture: Clinical management of obesity-associated hypertension, First Session of the
Working Group on Obesity: Obesity and Hypertension, XVI European Meeting on
Hypertension, Madrid, June 12-15, 2006
19. Speaker: Importance of Body Shape in Management of Chronic Diseases. International
Symposium on CVD, Stroke and Diabetes. New Delhi, India, February 2006.
20. Chair: Symposium on Diabetes, Metabolic Syndrome, Overweight and Obesity. International
Symposium on CVD, Stroke and Diabetes. New Delhi, India, February 2006.
21. Speaker: Abdominal Adiposity and Cardiovascular Risk: Is the BMI obsolete? Cardiology
Congress. Linz, Austria, January 2006.
22. Speaker: Management of Metabolic Disorder: Endocannabinnoid System. 3rd Scientific
Meeting of the Malaysian Society of Hypertension. Kuala Lumpur, Malaysia, January
2006
23. Speaker: Hypertension, Metabolic Syndrome and the Risk of Developing Diabetes: Is it Time
to Change the Guidelines?” 3rd Scientific Meeting of the Malaysian Society of
Hypertension. Kuala Lumpur, Malaysia, January 2006.
24. Chair: 4th International Symposium on Obesity and Hypertension. Berlin, Germany,
October 2005.
25. Speaker: Addressing the Metabolic Challenges of Obesity Using Pharmacotherapy. NAASO
Annual Meeting. Vancouver, Canada, October 2005.
26. Speaker: Current and future therapies for obesity. World Congress of Gastroenterology
2005 Meeting. Montreal, Canada, September 2005
27. Discussant at session: How I do it: Obesity Surgery. World Congress of Gastroenterology
2005 Meeting. Montreal, Canada, September 2005.
Arya M. Sharma, MD/PhD
Page 17
28. Chair of session: Global epidemiology and mechanisms of obesity. World Congress of
Gastroenterology 2005 Meeting. Montreal, Canada, September 2005.
29. Clinical challenges in devising drug dosing regimens for obese patients. 34th Annual
Meeting of the American College of Clinical Pharmacology. Rockville, USA, September
2005.
30. Hypertension management in the diabetic obese patient. 27th Annual Meeting of the
European Society of Cardiology. Stockholm, Sweden, September 2005.
31. The rationale for angiotensin blockade in the management of obese hypertensives
(presentation). 15th European Society of Hypertension Meeting. Milan, Italy, June 2005.
32. Chairman: Oral Session A on Obesity. 15th European Society of Hypertension Meeting.
Milan, Italy, June 2005.
33. Hypertension at the intersection of diabetes, obesity and renal failure (satellite symposium).
15th European Society of Hypertension Meeting. Milan, Italy, June 2005.
34. Role of RAS-blockade in the prevention of diabetes. 48th Annual Meeting of the Japan
Diabetes Society. Kobe, Japan, May 2005.
35. Abdominal obesity: A new assessment for CV risk factors management. European Congress
on Obesity. Athens, Greece, May 2005.
36. Cardiovascular benefit risk assessment of anti-obesity agents. Global CVCT Forum. Cannes,
France, April 2005.
37. Abdominal Obesity: Key determinants of the metabolic syndrome. American College of
Cardiology. Orlando, USA, March 2005.
38. Behaviour and Cardiovascular Risk. Teaching Faculty of Cardiology Update 2005. Davos,
Switzerland, February 2005.
39. Obesity and the Metabolic Syndrome: Epidemic in the United States. 37th Annual New York
Cardiovascular Symposium, American College of Cardiology. New York City, USA,
December 2004.
40. Insulin Resistance and Hypertension: Casual or Non-Casual Association? 2nd Annual World
Congress on the Insulin Resistance Syndrome. Los Angeles, USA, November 2004.
41. Prevention of Cardiovascular Disease. The Practice of Evidence-based Cardiology. Zurich,
Switzerland, June 2004.
42. Case management in patients with obesity. (Moderator of workshop) The Practice of
Evidence-based Cardiology. Zurich, Switzerland, June 2004.
43. Insulin Resistance in Hypertensive Patients. 14th European Meeting on Hypertension
(ESH), Paris France, June 2004.
44. Obesity and Hypertension, the pharmacological targets. 14th European Meeting on
Hypertension (ESH), Paris, France, June 2004.
45. Obesity, Hypertension and Insulin Resistance. IFECC. – Eighth International Forum for
the Evaluation for Cardiovascular Care: The Burden of Diabetes, Metabolic
Syndrome and Blood Pressure. Monte Carlo, January, 2004
46. Obesity and Hypertension; Diabetes and Obesity (two separate presentations). 13th
European Meeting on Hypertension (ESH), Milan, Italy, June 2003.
47. The Adipose-Tissue Renin-Angiotensin System in Hypertension and Diabetes. 46th Meeting
of the Japanese Society of Diabetes, Toyama, Japan, May 2003.
48. Advances in Cardiovascular Therapeutics: From the Bench to Clinical Outcome Trials. 18th
Annual Scientific Meetings of the American Society of Hypertension, New York, USA,
May 2003.
49. Role of Inflammatory Factors in Obesity-Associated Cardiovascular Disease. 15th Scientific
Meeting of the Inter-American Society of Hypertension, San Antonio, USA, April 2003.
50. Advances in the Pathogenesis of Hypertension in the Obese Subject. 8th National Meeting
of the Spanish Society of Hypertension and Spanish League Against Hypertension,
Valencia, Spain, March 2003
51. Angiotensin II: A Determinant of Vascular and Metabolic Risk in Diabetes? 4th International
Diovan Symposium, Seville, Spain, February 2003.
52. 3rd International Forum on Angiotensin II Receptor Antagonism. European Society of
Hypertension, Monte Carlo, January 2003.
53. Cardiovascular Risk and Its Management. The Australian Health and Medical Research
Congress, Melbourne, Australia, November 2002
54. Cardiovascular Risk Factors. 34th International Symposium on Growth Hormone and
Growth Factors in Endocrinology and Metabolism, Budapest, Hungary, October 2002
55. Individualized Treatment of Obesity: Fact or Fiction? Institute Pasteur Euroconference:
Pharmacogenomics: The Promise and Reality of Individualized Treatment, Paris,
France, October 2002
56. Pathophysiological Aspects of Obesity. 7th Annual Meeting of the European Council for
Blood Pressure and Cardiovascular Research, Seeheim, Germany, October 2002
Arya M. Sharma, MD/PhD
Page 18
57. Cardiovascular Changes Associated with the Metabolic Syndrome. National Taiwan
University Hospital, Taipei, Taiwan, July 2001
58. Chairman and Speaker: Genetics of Hypertension. XXXVIII Congress of the European
Renal Association and European Dialysis and Transplantation Association, Vienna,
Austria, June 2001
59. Chairman: Topical Workshop on Obesity and Hypertension. 11th Scientific Meeting of the
European Society of Hypertension, Milan, Italy, June 2001
60. Obesity and Hypertension: New Insights. Joint Scientific Meeting of the Netherlands and
Belgian Associations for the Study of Obesity, Antwerp, Belgium, May 2001
61. Choice of Antihypertensive Drug Therapy for the Obese Patient. 16th Scientific Meeting of
the American Society of Hypertension, San Francisco, USA, May 2001
62. Managing the Obese Hypertensive Patient. Meeting of the Thailand Cardiology
Physicians Association, Bangkok, Thailand, March 2001
63. Where Does the Role of RAS Polymorphis Stand Now? 2nd International Forum on
Angiotensin II Receptor Antagonism, Monte-Carlo, Italy, January 2001
64. Pathophysiology and Management of Obesity Hypertension. 4th International Symposium
of the South Asian Society of Atherosclerosis and Thrombosis, Mumbai, India,
December 2000
65. Multifactorial Approach to the Obese Hypertensive. Meeting of the Chinese Cardiology
Association, Shanghai, China, November 2000
66. Genetics of RAS in Human Hypertension, Topical Workshop on Genetics of Hypertension.
10th European Society of Hypertension Meeting, May 2000, Gothenburg
67. The Renin Angiotensin System and its Relation to Obesity Induced Hypertension. 10th
European Congress on Obesity, Antwerp, Belgium, May 2000
68. Adipose Tissue Cellularity and Function, Review Symposium. 10th European Congress on
Obesity, Antwerp, Belgium, May 2000
69. Genetics of Essential Hypertension. Uehara-Memorial Symposium, Tokyo, Japan, June
1999
70. Drug Therapy of Hypertension: How do we choose? 11th South African Hypertension
Society Congress, Durban, South Africa, March 1999
71. Role of Genetic Factors in Hypertension. 11th South African Hypertension Society
Congress, Durban, South Africa, March 1999
72. Renin-Angiotensin System and Progression of Renal Disease. 11th South African
Hypertension Society Congress, Durban, South Africa, March 1999
National Conferences/Symposia
73. Chairman: Obesity: Complications and Consequences, 3rd Annual Endocrinology Canada
International Symposium: Endocrinology, Metabolism and Oncology, Toronto, November 1617, 2006
74. Meet the Prof luncheon: Approaches to the treatment of obesity, 3rd Annual Endocrinology
Canada International Symposium: Endocrinology, Metabolism and Oncology, Toronto,
November 16-17, 2006
75. Speaker: Definitions and practical approaches to obesity, 3rd Annual Endocrinology
Canada International Symposium: Endocrinology, Metabolism and Oncology, Toronto,
November 16-17, 2006
76. Plenary lecture: The Metabolic Syndrome and the Canadian Obesity Network. Federal Food
Safety and Nutrition Research Meeting, Ottawa, Ontario, October 2006.
77. Organizer and Faculty: 1st Canadian Obesity Network Summer Boot Camp, Dushesnay,
Quebec, July 16-24, 2006
78. Workshop Moderator: The Canadian Obesity Network, Advancing Obesity and Chronic
Disease Knowledge through Teams-based Research, CIHR-INMD Teams Meeting, King
City, ON, July 5-7, 2006
79. Speaker: Medical Management of Obesity. Canadian Society for Clinical Nutrition 5th
Annual Meeting, Edmonton, Canada, May 2006.
80. Speaker: The Promise of Renin Inhibition: A New Approach to BP Control and Beyond.
Canadian Cardiovascular Congress Symposium. Montreal, Canada, October 2005.
81. Speaker: Advancing Diabetes Management. CDA/CSEM Professional Conference and
Annual Meeting. Edmonton, Canada, October 2005.
82. The Pharmacological Approach to Obesity Treatment. 4th Annual Scientific Meeting of the
Canadian Society for Clinical Nutrition. Montreal, Canada, September 2005.
83. Expression von kreislaufrelevanten Genen in humanem Fettgewebe. Konsortiumtreffen:
Molekulare Mechanismen der Gewichtsregulation, Marburg, Germany, March 2001
84. Diagnostik der Adipositas. 48. Deutscher Ärztekongreß Berlin, Berlin, May 1999
Rounds/Continuing Medical Education
Arya M. Sharma, MD/PhD
Page 19
85. Keynote Speaker: Obesity and the cardiometabolic risk: managing the epidemic, 20th Annual
Cardiology Update, Edmonton, November 25 2006
86. Speaker: 51st Annual Ontario Anesthesia Meeting, Hamilton, September 2006
87. Keynote Presenter: CME At Sea “Obesity Update”, Alaska, August 2006 (5 lectures and 1
workshop):
-Epidemiology and Societal Determinants of Obesity
-Neurobiology of Energy Regulation: Why Diets Don’t Work
-Medical Consequences of Obesity
-Medical Treatment of Obesity
-Surgical Treatment of Obesity
-Clinical Assessment and Care Discussion (workshop)
88. CME: Obesity Update 2006, Beamsville, ON, July 12, 2006 (Abbott Laboratories)
89. Obesity Treatments, 2nd McMaster Bariatric Conference, Hamilton, April 20 2006
90. Cardiology Rounds, Mt Sinai Hospital, Toronto, February 24 3006
91. The Current Epidemic and Challenge of Obesity. The 3rd Symposium on The Practice of
Evidence-based Cardiology for the Clinician, Toronto, Canada, June 2004.
92. Pharmacological Management of Obesity, Grey Bruce Health System, Video Conference,
Chesley, Durham, Kincardine, Lionshead, Listowel, Markdale, Meaford, Owen Sound,
Southhampton, Walkerton, Wiarton, June 16, 2006 (Abbott Laboratories)
93. Obesity Management, Burlington, March 21, 2006 (Abbott Laboratories)
94. Obesity Management, Oakville, March 14, 2006 (Abbott Laboratories)
95. Obesity and metabolic risk, St Catherines, March 1 2006 (Astra Zeneca)
96. Einfluss des Fettgewebes auf die kardiovaskuläre Regulation, Lecture: Grundlagen der
ernährungsphysiologischen Bewertung. Max-Planck-Institut fur Molekulare Genetik,
Berlin, Germany, March 2001
97. Besonderheiten der antihypertensiven Therapie bei Adipositas. Lecture: 64 Sitzung,
Nephrologisches Forum, Akademisches Lehrkrankenhaus, Munich, Germany
98. Hypertonie und Adipositas, Lecture, Universitätsklinikum Tübingen,.Tübingen, Germany,
9.1.2001
99. Adipositas - Ursachen und Risiken -, 25. Weißenseer Kolloquium, Berlin, June 1999
PUBLIC OUTREACH AND KNOWLEDGE TRANSLATION
Recent Talks to (Non-Medical) Professional Audiences
1.
2.
Obesity on Trial, George Brown College, Toronto, February 28,2006
Diagnosen ohne Therapie? Mikroarrays für die Klinik. Forum „Die Zeit“, Medica 2000,
23.11.2000, Düsseldorf, Germany
Recent Talks to Lay Audiences
3.
What is Obesity?” 2nd Annual Science in the City Lecture, sponsored by the Hamilton
Spectator, Hamilton, Ontario, November 14, 2006
4. A Beginner's Guide to Waist Management, MiniMed School, McMaster University, Hamilton,
April 18 2006
5. Obesity Forum, Hamilton General Hospital, January 31, 2006
6. The Canadian Obesity Network, Beef Information Centre (webscast), January 24, 2006
7. Obesity and the metabolic syndrome, Burlington Public Library, January 17, 2006
Recent Media Interviews
1. CV disease and the obesity epidemic, Anne Maria Tremonti, CBC 1 Radio Toronto, Dec. 12,
2006
2. Thesis competition, Anne Tobin, Canadian Press, Aug. 9,2006
3. Obesity and Heart Disease, Anne Mullens, Reader’s Digest, Canada, Aug 4, 2006
4. BMI vs. WHR, Helen Foster, NOW Magazine, UK, July 31, 2006
5. Diagnostic Equipment, Phil Meighan, Wave 94.7 FM, Hamilton, July 31, 2006
6. Bariatric Surgery, National Post, July 24, 2006
7. Bariatric Clinic, Joana Frketich, Hamilton Spectator, July 14, 2006
8. Obesity Treatments, Marisa Zucaro, Global News, Toronto, July 13, 2006
9. Obesity Treatments in Canada, Christina Cherneskey (Producer Cale Fair), News Talk 1010
CFRB, July 12, 2006
10. Canadian Obesity Network, Interview for Toronto Sun, July 8, 2006
11. Canadian Obesity Network, Interview for Lab Business Magazine, Lisa D’innocenzo, June
22, 2006
12. INTERHEART Study, Interview for Fitness Magazine, Anne Marie O’Connor, June 19, 2006
Arya M. Sharma, MD/PhD
Page 20
13. June 13-06 StatsCan CHS-Report on Obesity. NEWS FM 88.9 (Tom Young), Moncton, New
Brunswick, June 19, 2006
14. Obesity research, Burlington Post (Jason Misner), Burlington, February 6, 2006
15. Obesity surgery, National Post (Anne-Marie Owens), Toronto, January 30, 2006